<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000100060</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.04.014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto terapéutico del alprostadil en pacientes con isquemia crítica terminal de los miembros inferiores]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapeutic effect of alprostadil in patients with critical lower limb ischemia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Karles-Ernotte]]></surname>
<given-names><![CDATA[Alfredo J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bermúdez-Posada]]></surname>
<given-names><![CDATA[Aníbal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincón-Sánchez]]></surname>
<given-names><![CDATA[Héctor M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Padilla-Castro]]></surname>
<given-names><![CDATA[Andrea T.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Drews-Elger]]></surname>
<given-names><![CDATA[Katherine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Novoa-Leal]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hiller-Correa]]></surname>
<given-names><![CDATA[Heinz G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica El Rosario  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad CES Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad CES Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>60</fpage>
<lpage>65</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000100060&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  El manejo de la isquemia crítica de los miembros inferiores representa un reto para el cirujano vascular debido a la alta tasa de amputaciones y mortalidad. Las opciones de manejo actuales: puente femorodistal, angioplastia con o sin la colocación de Stents y la resección de la placa con láser o de manera mecánica, presentan a largo plazo una tasa de éxito muy baja y un número de amputaciones supracondíleas que continúa siendo elevado.  Métodos:  Para este estudio prospectivo se reclutaron 173 pacientes con diagnóstico de estadio avanzado, con isquemia crítica de miembro inferior quienes fueron tratados con alprostadil (60- 120 mcgr/día) por vía intravenosa sistémica por 28 días. La respuesta se midió clínicamente por mejoría del llenado capilar y con el uso de la escala análoga visual del dolor.  Resultados:  Al momento del alta hospitalaria el 94.3% de los pacientes mejoró el puntaje en la escala análoga visual del dolor (p &lt; 0.0001). El seguimiento a más de un año del tratamiento con alprostadil mostró que el 97% de los pacientes mejoró significativamente su estadio de isquemia, evitándose así una amputación mayor. No se observó respuesta al tratamiento en pacientes previamente intervenidos por vía endovascular (5 pacientes).  Conclusiones:  El tratamiento de pacientes con isquemia crítica de miembro inferior con alpostadil por infusión intravenosa, con bolos diarios de entre 60 y 120 mcg durante 28 días, este medicamento es seguro y presenta mínimos efectos secundarios. Esta terapia mejora sustancialmente el estadio funcional de Rutherford en estos pacientes y evita amputaciones mayores.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objetive: Management of critical lower limb ischemia represents a challenge for the vascular surgeon due to the high rate of amputations and mortality. Current management options include femorodistal bypass, angioplasty with or without stent and laser or mechanical resection of the plaque. They present a low success rate in the long run and a number of supracondylar amputations that still remains high.  Methods:  This prospective study included 173 patients diagnosed with advanced stage critical lower limb ischemia who were treated with systemic intravenous alprostadil (60 - 120 mcg/day) during 8 days. Response was measured clinically with improvement of capillary refill and using the visual analog scale for pain.  Results:  Upon discharge 94.3% of patients improved their visual analogue scale score for pain (p &lt; 0.0001). Follow-up for more than a year of alprostadil treatment revealed that 97% of patients significantly improved their ischemia status, thus avoiding further amputation. No response to treatment was observed in patients who had previously undergone endovascular surgery (5 patients). Conclusions: Treating patients with critical lower limb ischemia with intravenous alprostadil, administering daily doses of between 60 and 120 mcg during 28 days shows that this drug is safe and causes minimal secondary effects. This therapy significantly improves Rutherford&#8217;s function state in these patients and avoids further amputations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad arterial periférica]]></kwd>
<kwd lng="es"><![CDATA[Isquemia]]></kwd>
<kwd lng="es"><![CDATA[Prostaglandinas]]></kwd>
<kwd lng="es"><![CDATA[Reperfusión]]></kwd>
<kwd lng="en"><![CDATA[Peripheral artery disease]]></kwd>
<kwd lng="en"><![CDATA[Ischemia]]></kwd>
<kwd lng="en"><![CDATA[Prostaglandins]]></kwd>
<kwd lng="en"><![CDATA[Reperfusion]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Medical treatment of critical limb ischemia current state and future directions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangiafico]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Mangiafico]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Current vascular pharmacology]]></source>
<year>2011</year>
<volume>9</volume>
<page-range>658-76</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Medical and endovascular management of critical limb ischemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lumsden]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Peden]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists]]></source>
<year>2009</year>
<volume>16</volume>
<numero>II</numero>
<issue>II</issue>
<page-range>31-62</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egorova]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
<name>
<surname><![CDATA[Guillerme]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gelijns]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morrissey]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dayal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McKinsey]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of vascular surgery.]]></source>
<year>2010</year>
<volume>51</volume>
<page-range>878-85</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Critical limb ischemia definition and natural history. Current drug targets]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Milio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovascular &amp; haematological disorders]]></source>
<year>2004</year>
<volume>4</volume>
<page-range>219-25</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Critical limb ischemia: medical and surgical management.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slovut]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<source><![CDATA[Vascular medicine]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>281-91</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Understanding objective performance goals for critical limb ischemia trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conte]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<source><![CDATA[Seminars in vascular surgery]]></source>
<year>2010</year>
<volume>23</volume>
<page-range>129-37</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treating femoropopliteal disease: established and emerging technologies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diamantopoulos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Katsanos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Seminars in interventional radiology]]></source>
<year>2014</year>
<volume>31</volume>
<page-range>345-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The ongoing battle between infrapopliteal angioplasty and bypass surgery for critical limb ischemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schamp]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Meerwaldt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reijnen]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Geelkerken]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Zeebregts]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Annals of vascular surgery]]></source>
<year>2012</year>
<volume>26</volume>
<page-range>1145-53</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The angiosome concept in clinical practice implications for patient-specific recanalization procedures]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of cardiovascular surgery]]></source>
<year>2013</year>
<volume>54</volume>
<page-range>567-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PGE(1) short term therapy in critical lower limb ischemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bandiera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Forletta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Paola]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Cirielli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[International angiology: a journal of the International Union of Angiology.]]></source>
<year>2003</year>
<volume>22</volume>
<page-range>58-63</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mlekusch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Schillinger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sabeti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Awami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gschwandtner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Minar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Zeitschrift fur Gefasskrankheiten]]></source>
<year>2004</year>
<volume>33</volume>
<page-range>131-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creutzig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmacher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Elze]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Zeitschrift fur Gefasskrankheiten]]></source>
<year>2004</year>
<volume>33</volume>
<page-range>137-44</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intra-arterial prostaglandin e(1) infusion in patients with rest pain: short-term results]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatziioannou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dalakidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Katsenis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Koutoulidis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mourikis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[The Scientific World Journal]]></source>
<year>2012</year>
<numero>803678</numero>
<issue>803678</issue>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prostanoids for intermittent claudication]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[The Cochrane database of systematic reviews]]></source>
<year>2013</year>
<volume>4</volume>
<numero>CD000986</numero>
<issue>CD000986</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makino]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hashiya]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yamasaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hiraoka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Hypertension research: official journal of the Japanese Society of Hypertension]]></source>
<year>2004</year>
<volume>27</volume>
<page-range>85-91</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease randomised study of 86 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petronella]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Freda]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nunziata]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Antropoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Manganiello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cutolo]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
</person-group>
<source><![CDATA[Nutrition, metabolism, and cardiovascular diseases: NMCD]]></source>
<year>2004</year>
<volume>14</volume>
<page-range>186-92</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease VASA]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schror]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hohlfeld]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Zeitschrift fur Gefasskrankheiten]]></source>
<year>2004</year>
<volume>33</volume>
<page-range>119-24</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[[Intravenous PGE-1 in peripheral vascular obstructive disease: use over a 6-month period]]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llorente Gutiérrez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González Fernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes Irigoyen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez Caballero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacia hospitalaria órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria]]></source>
<year>2004</year>
<volume>28</volume>
<page-range>188-91</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prostanoids for critical limb ischaemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruffolo]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ciapponi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[The Cochrane database of systematic reviews]]></source>
<year>2010</year>
<numero>CD006544</numero>
<issue>CD006544</issue>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of alprostadil on ischemia-reperfusion injury of peripheral nerve in rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milcan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arslan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bagdatoglu]]></surname>
<given-names><![CDATA[OT]]></given-names>
</name>
<name>
<surname><![CDATA[Bagdatoglu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Polat]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kanik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacological research.]]></source>
<year>2004</year>
<volume>49</volume>
<page-range>67-72</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Patient-based outcomes using the Walking Impairment Questionnaire for patients with peripheral arterial occlusive disease treated with Lipo-PGE1]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shigematsu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation journal: official journal of the Japanese Circulation Society]]></source>
<year>2010</year>
<volume>74</volume>
<page-range>365-70</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biological responses in stented arteries]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaabane]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Otsuka]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Virmani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bochaton-Piallat]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovascular research]]></source>
<year>2013</year>
<volume>99</volume>
<page-range>353-63</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hemodynamic effects of a prostacyclin analog (Prostavasin) in systemic scleroderma patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salera]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Argalia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giuseppetti]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<source><![CDATA[La Radiología Médica]]></source>
<year>2005</year>
<volume>110</volume>
<page-range>106-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
